Drofenine

Synonyms: Cycloadiphene; Hexahydroadiphenine
Drofenine (Cycloadiphene; Hexahydroadiphenine) 是一种可穿透血脑屏障的解痉剂,作为 Kv2.1 通道抑制剂对人源靶点的 IC50 为 9.53 μM,同时也是丁酰胆碱酯酶 (BChE) 抑制剂(Ki 为 0.003 mM)和 TRPV3 激活剂,可通过阻断 Kv2.1 依赖性钾离子外流、抑制 Kv2.1/JNK/NF-κB 及 IkBa/NF-kB 信号通路并下调 Kv2.1 mRNA/蛋白的表达水平,抑制寡聚体 Aβ 诱导的小胶质细胞 NLRP3 炎性小体激活及神经元 Tau 过度磷酸化,从而改善认知障碍、促进神经突生长,并可诱导角质形成细胞钙内流及对其产生细胞毒性,改善糖尿病周围神经病变样病理改变,可用于阿尔茨海默病、糖尿病周围神经病变和平滑肌痉挛的相关研究。
产品编号: MS-F42796 CAS No.: 1679-76-1 分子式: C20H31NO2 分子量: 317.47
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Drofenine (Cycloadiphene; Hexahydroadiphenine) 是一种可穿透血脑屏障的解痉剂,作为 Kv2.1 通道抑制剂对人源靶点的 IC50 为 9.53 μM,同时也是丁酰胆碱酯酶 (BChE) 抑制剂(Ki 为 0.003 mM)和 TRPV3 激活剂,可通过阻断 Kv2.1 依赖性钾离子外流、抑制 Kv2.1/JNK/NF-κB 及 IkBa/NF-kB 信号通路并下调 Kv2.1 mRNA/蛋白的表达水平,抑制寡聚体 Aβ 诱导的小胶质细胞 NLRP3 炎性小体激活及神经元 Tau 过度磷酸化,从而改善认知障碍、促进神经突生长,并可诱导角质形成细胞钙内流及对其产生细胞毒性,改善糖尿病周围神经病变样病理改变,可用于阿尔茨海默病、糖尿病周围神经病变和平滑肌痉挛的相关研究。

生物实验数据

生物活性 Drofenine (Cycloadiphene; Hexahydroadiphenine) is a blood-brain barrier-permeable antispasmodic agent that acts as a Kv2.1 channel inhibitor with an IC50 of 9.53 μM against the human target, a butyrylcholinesterase (BChE) inhibitor with a Ki of 0.003 mM, and a TRPV3 activator; it blocks Kv2.1-dependent potassium efflux, inhibits the Kv2.1/JNK/NF-κB and IkBa/NF-kB signaling pathways, downregulates Kv2.1 mRNA/protein expression levels, suppresses oligomeric Aβ-induced microglial NLRP3 inflammasome activation and neuronal Tau hyperphosphorylation, thereby improving cognitive impairment and promoting neurite outgrowth, and it also induces calcium influx in keratinocytes and exerts cytotoxicity on them, ameliorates diabetic peripheral neuropathy-like pathological changes, and can be used for research related to Alzheimer's disease, diabetic peripheral neuropathy, and smooth muscle spasm.
IC50 & Target

KV2.1

9.53 μM ()

BChE

3 μM ()

TRPV3

 

NLRP3

 

体外研究
(In Vitro)

Drofenine (10 μM; 0.5 h) 可通过阻断 oligomeric Aβ (o-Aβ) 诱导的 Kv2.1 通道失活延迟,抑制 o-Aβ 对 CHO-Kv2.1 细胞中 Kv2.1 依赖性外向钾电流及电流密度的增强作用。
Drofenine (5-20 μM; 30 min) 可抑制 CHO-Kv2.1 细胞的膜电位,但对正常 CHO 细胞无影响。
Drofenine (5-20 μM) 不会降低 CHO-Kv2.1 细胞的存活率。
Drofenine (1-10 μM) 可强效抑制 CHO-Kv2.1 细胞中的 Kv2.1 通道电流,其 IC50 为 9.53 μM。
Drofenine (1-10 μM) 在可有效抑制 Kv2.1 的浓度下,对 CHO-Kv2.2 细胞中的 Kv2.2 通道电流仅表现出极弱的抑制作用,表明其对 Kv2.1 具有选择性。
Drofenine (0.01-0.1 mM) 是纯化人血清丁酰胆碱酯酶的纯竞争性抑制剂,其 Ki 值为 0.003 mM。
Drofenine (30-1000 μM) 是过表达 TRPV3 的 HEK-293 细胞中人类 TRPV3 的选择性激动剂,可激活钙通量,其 EC50 为 207 μM;在浓度高达 1000 μM 时,不会激活 TRPA1、TRPM8、TRPV1、TRPV2 或 TRPV4。
Drofenine (30-1000 μM) 可作为 HaCaT 人角质形成细胞中内源性 TRPV3 的强效激动剂,诱导钙通量,其 EC50 为 605 μM。
Drofenine (10-1000 μM; 24 h) 对 HaCaT 人角质形成细胞具有细胞毒性,孵育 24 小时后的 LC50 约为 230 μM。

Cell Viability Assay

Cell Line: human immortalized keratinocyte (HaCaT) cells
Concentration: 10-1000 μM
Incubation Time: 24 h
Result: Was more cytotoxic to HaCaT cells than 2-APB and carvacrol, with an LC50 of 230 μM, compared to LC50 values of >300 μmol/L for both 2-APB (MS-I70864) and carvacrol (MS-S47223).
体内研究
(In Vivo)

Drofenine (10 mg/kg/天;腹腔注射;每日给药;持续 8 周) 可通过抑制 Kv2.1/JNK/NF-κB 通路,改善 5xFAD 阿尔茨海默病小鼠的认知障碍、神经炎症、tau 蛋白病变、突触功能障碍及神经元丢失,且未观察到肝毒性或肾毒性。
Drofenine (10-20 mg/kg;共给药 4 次;STZ 注射后第 7、8、9、10 周) 可抑制背根神经节 (DRG) 组织中 Kv2.1 的表达与功能,促进 DRG 神经元轴突生长,并通过抑制 Kv2.1 改善 STZ (MS-Q80520) 诱导的 1 型糖尿病周围神经病变 (DPN) 小鼠的运动及感觉障碍。
Drofenine (10-20 mg/kg;共给药 4 次;研究周期的第 1、2、3、4 周) 可抑制 DRG 组织中 Kv2.1 的表达与功能,促进 DRG 神经元的轴突生长,并改善自发性 2 型 db/db DPN 小鼠的运动和感觉障碍。

Animal Model: 5xFAD transgenic (APPSwFlLon, PSEN1-M146L-L286V) (female, 7 months old at treatment start, Alzheimer's disease model); wild-type (WT) (female)
Dosage: 10 mg/kg/day
Administration: i.p.; daily; 8 weeks
Result: Improved short-term working memory via increased discrimination index in novel object recognition test.
Improved spatial working memory via increased number of novel arm crossings in Y-maze test.
Improved spatial learning and long-term memory via reduced escape latency in Morris water maze training trials and increased platform crossing frequency in Morris water maze probe trials in 5xFAD mice; no cognitive improvement observed in Kv2.1-knockdown 5xFAD mice.
Reduced Iba1-positive microglial and GFAP-positive astrocytic gliosis in 5xFAD mouse brains.
Reduced NLRP3-ASC positive puncta, and reduced protein levels of NLRP3, p-NLRP3, ASC, Cas1 (p20), IL-1β, p-JNK, and p-NF-κB in 5xFAD mice.
Reduced microglial NF-κB nuclear translocation in 5xFAD mice; no anti-inflammatory effects observed in Kv2.1-knockdown 5xFAD mice.
Reduced AT8-positive hyperphosphorylated Tau (Ser202/Thr205) areas in the hippocampus of 5xFAD mice.
Reduced protein levels of p396-Tau, p231-Tau, p199-Tau, p-GSK3β, and p-CaMKII-α in 5xFAD mice; no effects on Tau phosphorylation or related kinases observed in Kv2.1-knockdown 5xFAD mice.
Improved long-term potentiation induction and maintenance in the hippocampal DG region of 5xFAD mice.
Restored protein levels of synaptic markers PSD95, synaptophysin (SYN), and VAMP2 in 5xFAD mice; no synaptic improvement observed in Kv2.1-knockdown 5xFAD mice.
Reduced TUNEL-positive apoptotic neurons in 5xFAD mice.
Reversed loosely arranged neuronal nuclei (Nissl staining) in the hippocampus of 5xFAD mice; no effects on neuronal survival observed in Kv2.1-knockdown 5xFAD mice.
Showed no significant hepatotoxicity or nephrotoxicity via no changes in serum ALT, AST, or urea levels in treated WT or 5xFAD mice.
Animal Model: C57BL/6 (male, 7 weeks old at study initiation, streptozotocin-induced type 1 diabetes)
Dosage: 10 mg/kg; 20 mg/kg
Administration: 4 total doses; Weeks 7, 8, 9, 10 post-STZ injection
Result: Lowered Kv2.1/T-ERK ratios relative to vehicle-treated STZ mice.
Decreased relative Kv2.1 area in DRG tissue compared to vehicle-treated STZ mice.
Lowered relative Kv2.1 mRNA levels compared to vehicle-treated STZ mice.
Reduced elevated potassium currents in STZ mouse DRG neurons.
Increased total neurite length relative to vehicle-treated STZ mice.
Improved motor nerve conduction velocity relative to vehicle-treated STZ mice.
Reduced sensitivity to mechanical stimuli relative to vehicle-treated STZ mice.
Normalized thermal response relative to vehicle-treated STZ mice.
Animal Model: BKS Cg-m+/+Leprdb/J (db/db) (male, 17 weeks old at study initiation, spontaneous type 2 diabetes)
Dosage: 10 mg/kg; 20 mg/kg
Administration: 4 total doses; Weeks 1, 2, 3, 4 of study period
Result: Lowered Kv2.1/T-ERK ratios relative to vehicle-treated db/db mice.
Decreased relative Kv2.1 area in DRG tissue compared to vehicle-treated db/db mice.
Lowered relative Kv2.1 mRNA levels compared to vehicle-treated db/db mice.
Reduced elevated potassium currents at +50 mV in db/db mouse DRG neurons.
Increased total neurite length relative to vehicle-treated db/db mice.
Improved motor nerve conduction velocity relative to vehicle-treated db/db mice.
Reduced sensitivity to mechanical stimuli relative to vehicle-treated db/db mice.
Normalized thermal response relative to vehicle-treated db/db mice.

化学信息

分子量 317.47
分子式 C20H31NO2
CAS No. 1679-76-1
别名 Cycloadiphene; Hexahydroadiphenine

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础